These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9644010)

  • 21. Experts debate drugs for healthy women with breast cancer risk.
    Stephenson J
    JAMA; 1999 Jul; 282(2):117-8. PubMed ID: 10411178
    [No Abstract]   [Full Text] [Related]  

  • 22. Breast cancer hopes.
    Zurlinden J
    Nurs Spectr (Wash D C); 1998 Jun; 8(11):17-8. PubMed ID: 10542741
    [No Abstract]   [Full Text] [Related]  

  • 23. Of designer drugs, magic bullets, and gold standards.
    Rifkind BM; Rossouw JE
    JAMA; 1998 May; 279(18):1483-5. PubMed ID: 9600485
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevention of breast cancer in high-risk women.
    Kardinal CG; Veith R
    J La State Med Soc; 1999 Apr; 151(4):198-201. PubMed ID: 10234895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of antiestrogens for prevention of breast cancer.
    Reddy P; Chow MS
    Am J Health Syst Pharm; 2000 Jul; 57(14):1315-22; quiz 1323-5. PubMed ID: 10918921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Encouraging news from the SERM frontier. Selective estrogen receptor modulator.
    Franks AL; Steinberg KK
    JAMA; 1999 Jun; 281(23):2243-4. PubMed ID: 10376579
    [No Abstract]   [Full Text] [Related]  

  • 27. In search of the perfect SERM: beyond tamoxifen and raloxifene.
    McNeil C
    J Natl Cancer Inst; 1998 Jul; 90(13):956-7. PubMed ID: 9665139
    [No Abstract]   [Full Text] [Related]  

  • 28. Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
    Johansen AM
    Clin J Oncol Nurs; 2005 Jun; 9(3):317-20. PubMed ID: 15973842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Designer estrogens: breast cancer benefit, remaining questions.
    Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
    [No Abstract]   [Full Text] [Related]  

  • 30. In the clinic. Breast cancer screening and prevention.
    Nattinger AB
    Ann Intern Med; 2010 Apr; 152(7):ITC41. PubMed ID: 20368645
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase II evaluation of Ly156758 in metastatic breast cancer.
    Buzdar AU; Marcus C; Holmes F; Hug V; Hortobagyi G
    Oncology; 1988; 45(5):344-5. PubMed ID: 3412740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoporosis drugs show early promise.
    Rackoff P
    Lancet; 1997 Jun; 349(9067):1748. PubMed ID: 9213711
    [No Abstract]   [Full Text] [Related]  

  • 33. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oestrogen receptor and its selective modulators in gynaecological oncology.
    Seifert M; Galid A; Kubista E
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S66-7. PubMed ID: 11056325
    [No Abstract]   [Full Text] [Related]  

  • 35. Selective estrogen receptor modulators and prevention of invasive breast cancer.
    Gradishar WJ; Cella D
    JAMA; 2006 Jun; 295(23):2784-6. PubMed ID: 16754726
    [No Abstract]   [Full Text] [Related]  

  • 36. Gonadal hormone substitutes: effects on the cardiovascular system.
    Clarkson TB; Cline JM; Williams JK; Anthony MS
    Osteoporos Int; 1997; 7 Suppl 1():S43-51. PubMed ID: 9205646
    [No Abstract]   [Full Text] [Related]  

  • 37. Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.
    Jordan VC; Morrow M
    BMJ; 1999 Aug; 319(7206):331-2. PubMed ID: 10435938
    [No Abstract]   [Full Text] [Related]  

  • 38. Raloxifene vs tamoxifen.
    Goldstein SR
    JAMA; 2007 Jan; 297(3):263-4; author reply 264. PubMed ID: 17227974
    [No Abstract]   [Full Text] [Related]  

  • 39. Drugs for the gynecologist to prescribe in the prevention of breast cancer: current status and future trends.
    Goldstein SR
    Am J Obstet Gynecol; 2000 May; 182(5):1121-6. PubMed ID: 10819845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.